A DPEP1-Binding and mitochondria-targeted nanocomposite relieves acute respiratory distress syndrome by inhibiting Drp1-mediated mitochondria fission Authors: Ming He, Peng Zhang, Suya Bao, Rui Luo, Li Chen, Wenqi Huang, Weixi Jiang, An Zhang Published: 2026 ABSTRACT Acute respiratory distress syndrome (ARDS), a severe condition associated with high mortality, is characterized by uncontrollable inflammation and oxidative stress linked to mitochondrial dysfunction. Dynamin-related protein 1 (Drp1) drives pathological mitochondrial fission in patients with ARDS, leading to a sustained inflammatory response and excessive mitochondrial reactive oxygen species (mtROS) production. However, the specific inhibition of Drp1 in lung mitochondria remains challenging. Here, a multifunctional nanocomposite (DTP-LSA@MTC NPs) was developed by integrating the Drp1 inhibitor Mdivi-1 with a mitochondria-targeting tannic acid–cerium (TA-Ce) nanozyme network. Additionally, surface functionalization with an LSA peptide enabled specific binding to DPEP1 on the inflamed pulmonary endothelium, enhancing site-specific accumulation and competitively inhibiting neutrophil recruitment. Following intravenous administration, these nanoparticles efficiently targeted both pulmonary microvascular endothelial cells and mitochondria, suppressed the activity of the Drp1–NLRP3 inflammasome axis, and scavenged ROS, ultimately preventing the development of cytokine storms in preclinical models of ARDS. This targeted nanotherapeutic strategy offers a potent and translatable approach for treating ARDS and related inflammatory disorders. Introduction Acute respiratory distress syndrome (ARDS) is a life-threatening form of noncardiogenic pulmonary edema characterized primarily by damage to alveolar epithelial cells and pulmonary microvascular endothelial cells (HPMEC). Diverse intrapulmonary factors, such as pneumonia and aspiration, or extrapulmonary factors, including sepsis, acute pancreatitis, and trauma, may trigger ARDS. These insults result in severe hypoxemia, reduced lung compliance, increased arteriovenous shunting, and an expansion of the physiological dead space [[1], [2], [3], [4], [5], [6]]. Global epidemiological data indicate that ARDS accounts for 10.4% of all admissions to intensive care units (ICUs), with a 28-day mortality rate of 34.8% and an overall in-hospital mortality rate of 40.0%. Furthermore, the patient's mortality risk is markedly correlated with disease severity. Current standard therapeutic strategies for ARDS primarily include lung-protective ventilation and fluid resuscitation; these supportive interventions aim to stabilize vital signs and promote spontaneous lung tissue repair. However, insufficient control of key pathophysiological processes—particularly excessive inflammatory responses and oxidative stress (ROS)—can lead to progressive lung tissue injury and may precipitate systemic inflammatory response syndrome (SIRS) [[7], [8], [9], [10], [11], [12]]. Dynamin-related protein 1 (Drp1), encoded by the DNM1L gene, is a mechanochemical enzyme belonging to the dynamin-like GTPase family. The most functionally relevant of its posttranslational modifications is phosphorylation, particularly at serine residues Ser616 and Ser637. Phosphorylation at Ser616 facilitates the translocation of Drp1 to mitochondria, thereby promoting mitochondrial fission [13]. Under physiological conditions, moderate Drp1 phosphorylation supports basal mitochondrial fission and ATP production, maintaining cellular homeostasis. However, accumulating evidence indicates that mitochondrial Drp1 activation under ischemic and hypoxic stress conditions promotes binding to voltage-dependent anion channels (VDACs), leading to the dissociation of hexokinase 1 (HK1) from VDAC. Given that the HK1–VDAC interaction supports oxidative phosphorylation and metabolic stability, HK1 detachment triggers the activation of the NLRP3 inflammasome, initiating inflammatory responses. Simultaneously, mitochondrial ROS (mtROS) overproduction and mitochondrial DNA (mtDNA) release during inflammation further amplify proinflammatory signaling through NF-κB activation, forming a vicious cycle that exacerbates tissue injury [3,[14], [15], [16]]. Consequently, Drp1 is critically involved in the pathogenesis of multiple disorders, including ischemic organ injury [[17], [18], [19], [20]], neurodegenerative diseases [[21], [22], [23]], and inflammation-associated pathologies [[24], [25], [26]]. In patients with ARDS, the level of Drp1 phosphorylated at Ser616 in alveolar epithelial cells increases, leading to increases in mitochondrial fission and mitochondrial ROS production, which increase the levels of downstream inflammatory factors [27]. Furthermore, excessive Drp1 phosphorylation enhances macrophage polarization and promotes the apoptosis of alveolar epithelial cells [28,29]; however, research on the inhibition of ARDS through the suppression of the excessive phosphorylation of Drp1 in pulmonary endothelial cells remains limited. Mdivi-1 (MDI), a quinazolinone derivative, is a selective inhibitor of Drp1. It prevents excessive Ser616 phosphorylation, facilitates Ser637 dephosphorylation, and blocks Drp1 translocation to mitochondria, thereby maintaining mitochondrial integrity. However, the inherent drawbacks of MDI, namely, its poor water solubility, low bioavailability, and short half-life, severely limit its clinical application [30]. Tannic acid (TA), a natural polyphenolic compound, has potent antioxidant properties and can chelate metal ions. Notably, studies have demonstrated its strong binding affinity to mitochondrial outer membrane proteins [31]. Cerium (Ce), a rare earth element, can alternate between Ce3+ (reduced state) and Ce4+ (oxidized state), enabling the formation of nanocatalysts with both superoxide dismutase-like and catalase-like activities, thereby conferring an exceptional antioxidant capacity [32]. The incorporation of Ce into polyphenol-based polymer systems facilitates the construction of structurally tunable metal–polyphenol networks (MPNs), which exhibit precise controllability and efficient multienzyme-like activity, thereby mitigating oxidative stress in individuals with ARDS. Here, we successfully synthesized an optimized composite, DTP-LSA@MTC NPs, that integrates MDI with a TA–Ce nanozyme to enable the targeted downregulation of Drp1 expression for precise ARDS therapy [33,34]. In the initial assembly, TA and Ce self-organize into a network with high antioxidant efficiency and mitochondrial targeting ability. MDI is subsequently encapsulated within the hydrophobic core, while the TA–Ce nanozyme is embedded into the hydrophilic phase via a lipid shell, resulting in the formation of a multifunctional drug delivery system. Moreover, covalent conjugation of the LSA peptide (LSALTPSPSWLKYKAL) to 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine (DSPE) enables DTP-LSA@MTC NPs to specifically recognize and bind to the DPEP1 protein, which is overexpressed at inflammatory sites. Given that neutrophils adhere to and roll along pulmonary endothelial cells via an interaction with the DPEP1 receptor, the LSA peptide not only facilitates targeted localization but also competitively inhibits neutrophil recruitment during inflammation, effectively reducing excessive ROS generation [[35], [36], [37], [38], [39]]. Following intravenous administration, DTP-LSA@MTC selectively bind to DPEP1 on pulmonary endothelial cells via the LSA peptide ligand, enabling targeted cellular uptake. Under inflammatory conditions, elevated ROS trigger cleavage of the thioketal (TK) linker, resulting in controlled intracellular release of the payload. The liberated MDI inhibits Drp1 phosphorylation—thereby suppressing pathological mitochondrial fission—while TA-Ce nanozymes concurrently scavenge mtROS and preserve mitochondrial integrity through targeted accumulation. Moreover, intravenous administration enables LSA peptide–mediated systemic interception of activated neutrophils within the circulation, thereby preventing their pathological sequestration across multiple organs. Collectively, these coordinated mechanisms synergistically protect mitochondrial structure and function, leading to downstream suppression of NLRP3 inflammasome activation and mitigation of oxidative stress in ARDS (Fig. 1). The core contribution of this work lies in the rational integration of the broad-spectrum antioxidant activity of the TA-Ce nanozyme with the target-specific inhibition of Drp1 phosphorylation mediated by MDI. To the best of our knowledge, this strategy establishes a synergistic therapeutic platform capable of concurrently modulating upstream oxidative stress and downstream mitochondrial fission–driven inflammation in ARDS—thereby addressing key limitations of single-target interventions and providing a conceptually novel approach for the treatment of inflammatory disorders.Fig. 1Schematic illustration of the synthetic process and therapeutic mechanism of DTP-LSA@MTC NPs. Schematic illustration of the synthetic process and therapeutic mechanism of DTP-LSA@MTC NPs. Results and discussion Characterization of the nanoparticles In this study, proton nuclear magnetic resonance (1H NMR) spectroscopy was employed to verify the chemical structures of the LSA peptide and DSPE-TK-PEG2000-LSA conjugate. As shown in Fig. S1A, the 1H NMR spectrum clearly displays the characteristic resonance peaks of the LSA peptide, highlighted within the designated black box. Moreover, specific signals corresponding to TK, DSPE, and polyethylene glycol (PEG) moieties were observed in the regions with the expected chemical shifts, consistent with previously reported structural data. These analyses conclusively demonstrate the successful synthesis of DSPE-TK-PEG2000-LSA, which served as the primary functional component of the liposomal formulation. “DTP-LSA NPs” refers to the nanoparticle formulations prepared with DSPE-TK-PEG2000-LSA as the key functional component, where TK acts as a reactive oxygen species (ROS)-responsive linkage and LSA is the targeting peptide conjugated to PEG2000. In contrast, “DP NPs” denotes the control nanoparticle formulations that only contain PEG2000 in the liposomal raw materials, without the incorporation of either the TK ROS-responsive linkage or the LSA targeting peptide. Additionally, other relevant abbreviations for the components of nanoparticle formulations are defined as follows: “TC” indicates liposomes containing only TA-Ce; “MDI” indicates liposomes containing only Mdivi-1; and “MTC” indicates liposomes containing both TA-Ce and Mdivi-1. The properties of the nanoparticles (NPs) were subsequently evaluated. In terms of appearance, the lipid nanoparticles without TA-Ce were milky white, while those with TA-Ce were pale yellow. No obvious precipitation was observed after standing, indicating that the nanoparticles had good dispersibility, small particle sizes, and no significant aggregation (Fig. S2A). Transmission electron microscopy (TEM) images showed that the DTP-LSA@MTC NPs were spherical with smooth surfaces and a uniform morphology (Fig. 2a). In contrast, TA-Ce formed honeycomb-like aggregates, with a uniform distribution of carbon (C), oxygen (O), and cerium (Ce) (Fig. 2b). Subsequently, we evaluated the stability of DTP-LSA@MTC NPs in culture medium containing 10% FBS. No obvious aggregation was observed during the monitoring period, which confirmed that DTP-LSA@MTC NPs exhibit favorable stability under physiological conditions. This excellent stability is attributed to the hydrophilic surface modification of nanoparticles, which provides sufficient steric repulsion to inhibit particle aggregation in serum-containing medium. These findings indicate that DTP-LSA@MTC NPs can maintain stable properties during blood circulation, thus supporting their potential for targeted delivery to inflamed lung tissues for the treatment of ARDS (Fig. S1B). The actual Ce content in TA-Ce solutions synthesized with different concentrations of TA and Ce(SO4)2 was determined by ICP-OES. When TA-Ce was prepared with 24 mM TA and 24 mM Ce(SO4)2, the corresponding Ce concentration was 17.03 mg/L; at 48 mM and 96 mM, the measured Ce concentrations were 124.56 mg/L and 625.83 mg/L, respectively. Based on these results, we optimized the volume of TA-Ce used for liposome encapsulation. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) assays showed that the ROS scavenging rates were approximately 97%, 99%, and 95%, respectively, with no sharp increase in the scavenging rate with increasing concentration (Fig. S3A). Therefore, the lowest TA-Ce concentration was selected for subsequent experiments. Volumes of 0.5 mL, 1 mL, 2 mL, and 3 mL were tested to determine the optimal volume of TA-Ce added to liposomes. Double-distilled water was added to achieve a total volume of 4 mL (3.5 mL, 3 mL, 2 mL, and 1 mL of double-distilled water were added, respectively), followed by sonication. Obvious precipitation was observed in samples with 2 mL and 3 mL of TA-Ce, whereas no significant precipitation was detected in those with 0.5 mL and 1 mL of TA-Ce (Fig. S2B). ICP–OES analysis of the Ce content in the four samples revealed values of 7.8, 12.33, 13.36, and 38.60 mg/L, respectively. Based on these results, 1 mL of TA-Ce synthesized at 24 mM TA and Ce (SO4)2 was selected for liposome encapsulation, with an encapsulation efficiency of approximately 72.4% TA-Ce. DTP-LSA@MTC NPs were prepared by adding different amounts of MDI (1.0, 2.0, 3.0, or 5.0 mg) to 10 mg of liposomes. When 5 mg of MDI was added, the EE% and LE% of MDI were 92.46% and 30.82%, respectively. Although the encapsulation efficiency increased to 97.53% with 2 mg of MDI, the loading efficiency decreased to 16.26% (Fig. 2c). To reduce the cost of liposome production, 5 mg of MDI was selected for the preparation of DTP-LSA@MTC NPs and DTP-LSA@MDI NPs, resulting in an MDI/TA-Ce ratio of approximately 1:1.2 in DTP-LSA@MTC NPs. UV–visible (UV–vis) spectroscopy was used to obtain the absorption curves of MDI at various concentrations. The absorbance peak occurred at a wavelength of 295 nm (Fig. 2d). Thus, Fig. 2e presents the standard concentration curve of MDI at 295 nm, which was used to calculate the encapsulation efficiency (EE%) and loading efficiency (LE%). Absorption curves of TA-Ce at different concentrations had absorption peaks at 216 nm and 279 nm (Fig. 2f). The absorption peak at 216 nm was more stable than that at 279 nm. Therefore, Fig. 2g shows the standard concentration curve of TA-Ce at 216 nm. Dynamic light scattering (DLS) was used to determine the particle size and zeta potential of DTP-LSA NPs, DTP-LSA@TC NPs, DTP-LSA@MDI NPs, and DTP-LSA@MTC NPs. The average particle sizes were 208 nm, 245 nm, 290 nm, and 307 nm, respectively. The particle size increased slightly after the encapsulation of MDI and TA-Ce (Fig. 2h). No significant differences in particle size were observed between DTP-LSA@MDI NPs and DTP-LSA@MTC NPs. The average ζ potentials of the four types of NPs were −49.3 mV, −27.7 mV, −42.3 mV, and −25.9 mV, respectively. We found that TA-Ce increased the zeta potential of the nanoparticles (Fig. 2i). The encapsulation efficiencies in the control, 100 μM H2O2, and 200 μM H2O2 groups significantly decreased to 78.7%, 48.6%, and 39.5%, respectively (Fig. 2j). This finding indicates that in the presence of ROS, the TK bond is broken, leading to the release of MDI from DTP-LSA@MDI NPs. Thus, the encapsulation efficiency decreased significantly in the group treated with 200 μM H2O2. These data demonstrate that the synthesized nanoparticles exhibit a favorable particle size, zeta potential, and stability in electrolyte solutions, as well as excellent ROS-responsive drug release properties and ROS-scavenging ability. X-ray photoelectron spectroscopy (XPS) was used to analyze the elemental composition of TA-Ce and DTP-LSA@MTC NPs. The C/O/Ce ratios were 31.12:1407.08:14.47 for TA-Ce (Fig. 2k–n) and 123.94:47.97:19.03 for DTP-LSA@MTC NPs (Fig. 2o–r), indicating an increased proportion of Ce after liposome encapsulation. Additionally, the ratio of Ce3+ to Ce4+ in TA-Ce, it was 1:1.22, whereas in DTP-LSA@MTC NPs was 1:1.8, confirming the ability of the NPs to scavenge ROS. The ability of the nanoparticles to scavenge ROS was verified using electron spin resonance (ESR). The PBS control group showed a strong characteristic quartet of DMPO-OH (5,5-dimethyl-1-pyrroline N-oxide-hydroxyl radical adduct), indicating the effective generation and trapping of •OH. After the addition of TA-Ce, DTP-LSA@MDI NPs or DTP-LSA@MTC NPs, the intensity of the DMPO-OH signal decreased significantly. The signal reduction was most pronounced in the DTP-LSA@MTC NPs group, almost reaching the baseline level (Fig. 2s). A similar trend was observed for the superoxide anion (O2−•) systems (Fig. 2t) and singlet oxygen (1O2) (Fig. 2u). The ROS-responsive thioketal (TK) bonds incorporated within the liposomal lipid bilayer can directly react with and consume free radicals in the cell-free system, thereby contributing to the decreased radical signal detected in the ESR assay. Meanwhile, cleavage of the TK bonds in the reaction system triggers the controlled release of TA-Ce nanozymes. As a result, the DTP-LSA@MTC NPs group exhibits the strongest reactive oxygen species scavenging capability. To characterize the ROS-responsive drug release capacity of DTP-LSA@MTC NPs, we performed in vitro release studies by incubating the nanoparticles with H2O2 solutions at pathophysiologically relevant concentrations (100 μM and 200 μM) under continuous stirring, with the release profiles of TA-Ce and Mdivi-1 quantified at predetermined time points. In the control group (double-distilled water only), minimal drug release was observed over 72 h, with only 18% of TA-Ce and 20% of Mdivi-1 released, and the solution remained milky white, indicative of the structural stability of the nanoparticles under non-oxidative conditions. In stark contrast, exposure to H2O2 triggered a marked acceleration in drug release in a concentration-dependent fashion. At 72 h, cumulative release of TA-Ce reached 43% and 55% in the presence of 100 μM and 200 μM H2O2, respectively (Fig. S2D), while Mdivi-1 exhibited even greater release efficiency under the same conditions, with 51% and 60% of the drug released at 100 μM and 200 μM H2O2, respectively (Fig. 2j). Notably, both drugs displayed a biphasic release kinetics: an initial rapid burst phase within the first 12 h, likely driven by surface-associated drug release, followed by a slower, sustained release phase governed by gradual ROS-triggered degradation of the nanoparticle matrix. Corroborating these quantitative release data, the solution gradually transitioned from milky white to transparent as nanoparticle degradation progressed (Fig. S2C). These findings collectively confirm that DTP-LSA@MTC NPs possess excellent ROS-responsive drug release performance, supporting their potential for targeted drug delivery in oxidative stress-associated pathological microenvironments.Fig. 2Synthesis and characterization of NPs. (a) TEM image of DTP-LSA@MTC NPs; scale bar: 200 nm. (b) TEM image of TA-Ce; scale bar: 500 nm. (c) EE% and LE% of MDI in DTP-LSA@MTC NPs. (d) UV–vis absorption spectra of MDI at different concentrations. (e) Standard concentration curve of MDI. (f) UV–vis absorption spectra of TA-Ce at different concentrations. (g) Standard concentration curve of TA-Ce. The average (h) hydrodynamic size and (i) zeta potential of various NPs. (j) Cumulative drug release profile of DTP-LSA@MTC NPs in the presence of 100 and 200 μM H2O2. (k) XPS survey spectrum of TA-Ce. High-resolution XPS spectra of (l) Ce, (m) O, and (n) C in TA-Ce. (o) XPS survey spectrum of DTP-LSA@MTC NPs. High-resolution XPS spectra of (p) Ce, (q) O, and (r) C in DTP-LSA@MTC NPs. (s) Scavenging effects of PBS, TA-Ce, DTP-LSA@MDI NPs, and DTP-LSA@MTC NPs on (s) •OH, (t) •O2-, and (u) 1O2 as detected by EPR spectra. Data are presented as means ± SD, n = 3. Synthesis and characterization of NPs. (a) TEM image of DTP-LSA@MTC NPs; scale bar: 200 nm. (b) TEM image of TA-Ce; scale bar: 500 nm. (c) EE% and LE% of MDI in DTP-LSA@MTC NPs. (d) UV–vis absorption spectra of MDI at different concentrations. (e) Standard concentration curve of MDI. (f) UV–vis absorption spectra of TA-Ce at different concentrations. (g) Standard concentration curve of TA-Ce. The average (h) hydrodynamic size and (i) zeta potential of various NPs. (j) Cumulative drug release profile of DTP-LSA@MTC NPs in the presence of 100 and 200 μM H2O2. (k) XPS survey spectrum of TA-Ce. High-resolution XPS spectra of (l) Ce, (m) O, and (n) C in TA-Ce. (o) XPS survey spectrum of DTP-LSA@MTC NPs. High-resolution XPS spectra of (p) Ce, (q) O, and (r) C in DTP-LSA@MTC NPs. (s) Scavenging effects of PBS, TA-Ce, DTP-LSA@MDI NPs, and DTP-LSA@MTC NPs on (s) •OH, (t) •O2-, and (u) 1O2 as detected by EPR spectra. Data are presented as means ± SD, n = 3. In vitro targeting efficacy of DTP-LSA@MTC NPs To assess the expression profile of the DPEP1 receptor, the binding target of the LSA peptide, in the presence or absence of lipopolysaccharide (LPS) stimulation, we examined DPEP1 levels in human pulmonary microvascular endothelial cells (HPMEC) and human umbilical vein endothelial cells (HUVECs) using confocal laser scanning microscopy (CLSM) (Fig. 3b). HPMEC subjected to LPS induction displayed markedly stronger red fluorescence, indicating elevated DPEP1 expression, compared with the other three groups, among which no statistically significant differences were detected (Fig. 3a). These findings confirm that the LSA peptide specifically binds to DPEP1 on the pulmonary vascular endothelium, with a clear increase in binding affinity upon LPS stimulation. Then, the DTP-LSA@MTC NPs and DP@MTC NPs were labeled with Dil, a lipophilic fluorescent dye, for in vitro uptake studies to determine whether DTP-LSA@MTC NPs could effectively target the pulmonary vascular endothelium and whether TA-Ce complexes could achieve mitochondrial targeting following LPS stimulation. Intracellular nanoparticle internalization was quantified using CLSM and flow cytometry. Upon phagocytosis by LPS-induced HPMEC, Dil-labeled DTP-LSA@MTC NPs exhibited pronounced cell-shaped red fluorescence surrounding the nucleus, with the fluorescence intensity increasing over time. After 4 h, the cytoplasmic accumulation of the Dil-DTP-LSA@MTC NPs significantly increased. In contrast, LPS-induced HPMEC coincubated with Dil-DP@MTC NPs for 4 h exhibited negligible red fluorescence. In the LPS-induced HUVECs used as controls, neither the Dil-DTP-LSA@MTC NPs nor the Dil-DP@MTC NPs produced notable red fluorescence (Fig. 3d and e). The flow cytometry data were consistent with the CLSM observations (Fig. 3f), confirming the strong pulmonary endothelial affinity of DTP-LSA@MTC NPs following LPS stimulation. To assess the effect of LSA peptides on neutrophil competition inhibition, we assessed neutrophil migration in HPMEC monolayers using a Transwell assay. In the blank control group, baseline background levels were confirmed. In the positive control group, a considerable number of neutrophils migrated to the lower chamber in response to chemokine gradients. Treatment with untargeted nanoparticles did not significantly change the number of migrating neutrophils compared to the positive control. In contrast, treatment with LSA peptide-targeted nanoparticles resulted in a significant reduction in the number of migrating neutrophils (Fig. S4). Suggesting that LSA peptide-targeted nanoparticles could be used to reduce the number of migrating neutrophils, these results suggest that LSA peptide-targeted nanoparticles can effectively inhibit neutrophil transendothelial migration and reduce neutrophil aggregation. To further validate the mitochondrial targeting capability of the TA-Ce complex, TA-Ce was conjugated with fluorescein isothiocyanate (FITC) and incorporated into DTP-LSA@MTC NPs. Under CLSM, the mitochondria appeared red, whereas the FITC-labeled nanoparticles appeared green. In the FITC-only group, no detectable nanoparticle signal or red–green colocalization was observed, indirectly confirming successful FITC conjugation to the nanoparticles. In the TA-Ce-FITC group coincubated with HPMEC, slight overlap of red–green fluorescence was noted, whereas the colocalization intensity was significantly greater in the DTP-LSA@MTC-FITC NPs group (Fig. 3g). This increase reflects the encapsulation of TA-Ce in liposomes, which facilitates cellular uptake and mitochondrial binding. Conversely, minimal colocalization was detected in HUVECs cocultured with TA-Ce-FITC or DTP-LSA@MTC-FITC NPs. Collectively, these results indicate that DTP-LSA@MTC-FITC NPs can achieve dual targeting to pulmonary endothelial cells and mitochondria with high precision.Fig. 3In vitro evaluation of the targeting efficacy and cytotoxicity of DTP-LSA@MTC NPs. (a) Quantitative fluorescence intensity and (b) fluorescence images of DPEP1 expression in HPMEC and HUVECs after LPS stimulation, scale bars: 30 μm, n = 3. (c) Quantitative analysis for intracellular ROS generation after different treatments, n = 3. (d) Corresponding fluorescence intensity analysis and (e) fluorescence images of HPMEC and HUVECs incubated with Dil-labeled DTP-LSA@MTC NPs or DP@MTC NPs at different time points; scale bars: 30 μm, n = 3. (f) Intracellular uptake of Dil-labeled DTP-LSA@MTC NPs or DP@MTC NPs by HPMEC and HUVECs at different time points. (g) Fluorescence images showing mitochondria and FITC-labeled TA-Ce in HPMEC and HUVECs, scale bars: 10 μm. Cell viability of HPMEC, HUVECs and Raw264.7 cells following 24-h incubation with increasing concentrations of (h) Mdivi-1, (i) DTP-LSA@TC NPs, (j) DTP-LSA@MDI NPs, and (k) DTP-LSA@MTC NPs, n = 3. (l) Intracellular ROS generation in LPS-stimulated HPMEC, detected by DCFH-DA staining and analyzed via flow cytometry under different treatment conditions. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. In vitro evaluation of the targeting efficacy and cytotoxicity of DTP-LSA@MTC NPs. (a) Quantitative fluorescence intensity and (b) fluorescence images of DPEP1 expression in HPMEC and HUVECs after LPS stimulation, scale bars: 30 μm, n = 3. (c) Quantitative analysis for intracellular ROS generation after different treatments, n = 3. (d) Corresponding fluorescence intensity analysis and (e) fluorescence images of HPMEC and HUVECs incubated with Dil-labeled DTP-LSA@MTC NPs or DP@MTC NPs at different time points; scale bars: 30 μm, n = 3. (f) Intracellular uptake of Dil-labeled DTP-LSA@MTC NPs or DP@MTC NPs by HPMEC and HUVECs at different time points. (g) Fluorescence images showing mitochondria and FITC-labeled TA-Ce in HPMEC and HUVECs, scale bars: 10 μm. Cell viability of HPMEC, HUVECs and Raw264.7 cells following 24-h incubation with increasing concentrations of (h) Mdivi-1, (i) DTP-LSA@TC NPs, (j) DTP-LSA@MDI NPs, and (k) DTP-LSA@MTC NPs, n = 3. (l) Intracellular ROS generation in LPS-stimulated HPMEC, detected by DCFH-DA staining and analyzed via flow cytometry under different treatment conditions. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. In vitro therapeutic efficacy of DTP-LSA@MTC NPs To further verify the effect of DTP-LSA@MTC NPs on mitochondrial function, we systematically evaluated the effects of MDI, TA-Ce, DTP-LSA@MDI NPs, DTP-LSA@TC NPs, and DTP-LSA@MTC NPs on the viability of three cell lines, HPMEC, RAW264.7 cells, and HUVECs. MDI exhibited significant cytotoxicity, with a cell survival rate of approximately 50% after treatment with 10 μg/mL (Fig. 3h). However, when MDI was encapsulated in liposomes to form DTP-LSA@MDI NPs, the cell survival rate was significantly increased to 80%. These findings indicate that liposome encapsulation effectively reduces the cytotoxicity of MDI while increasing its biocompatibility, providing a safer basis for subsequent therapeutic applications. Additionally, TA-Ce (Fig. S5), DTP-LSA@TC NPs, and DTP-LSA@MTC NPs (Fig. 3i–k) showed no apparent cytotoxicity at conventional therapeutic concentrations, demonstrating good biosafety. Significant cytotoxicity was observed only when the concentration reached 200 μg/mL. These results further confirm that the prepared nanoparticles have excellent cytoprotective effects and can be safely used within the effective dose range. To investigate the effects of the nanoparticles on mitochondrial function, ROS levels were measured in HPMEC. We found that the LPS-induced group exhibited the strongest green fluorescence under the CLSM (Fig. S6) and a stronger signal using flow cytometry (Fig. 3l), indicating that LPS stimulation triggered a severe inflammatory response, leading to massive intracellular ROS accumulation. In contrast, both the TA-Ce treatment group and the MDI treatment group exhibited a significant reduction in ROS levels, indicating that these two drugs can effectively inhibit inflammatory responses and reduce oxidative stress (Fig. 3c). Furthermore, DTP-LSA@MDI NPs and DTP-LSA@TC NPs further enhanced the anti-inflammatory and antioxidant effects of the drugs. Notably, the DTP-LSA@MTC NPs treatment group showed the weakest green fluorescence, indicating its optimal therapeutic effects on mitochondrial protection and ROS scavenging. To further elucidate the protective effects of DTP-LSA@MTC NPs on mitochondrial function, we specifically determined mitochondrial reactive oxygen species (mtROS), which serve as crucial mediators of mitochondrial damage and oxidative stress. Consistent with the intracellular ROS detection results, the LPS-stimulated group presented markedly elevated mtROS signals, demonstrating that LPS intervention not only induces widespread intracellular oxidative stress but also specifically provokes excessive mtROS production within mitochondria. Such aberrant mtROS accumulation further aggravates mitochondrial dysfunction and establishes a vicious cycle between mitochondrial injury and oxidative stress. In comparison with the LPS-induced group, both free TA-Ce/MDI groups and liposome-encapsulated drug groups exerted evident mitochondria-targeted antioxidant effects, which broke the vicious cycle of mitochondrial damage and thus achieved superior protective efficacy on mitochondrial function (Fig. S6B). JC-1 is a fluorescent probe used to detect the mitochondrial membrane potential (ΔΨm). When mitochondrial function is normal, JC-1 aggregates in the mitochondrial matrix to form polymers, which emit red fluorescence. When mitochondria are damaged and the ΔΨm decreases, JC-1 exists as a monomer and emits green fluorescence. The results showed that the LPS-induced group had the strongest green fluorescence, indicating that LPS stimulation causes a collapse of the ΔΨm and severe mitochondrial dysfunction. In contrast, the DTP-LSA@MTC NP-treated group presented the weakest green fluorescence and the strongest red fluorescence, demonstrating its ability to protect mitochondrial function and maintain ΔΨm stability effectively (Fig. 4a and b). Additionally, compared with the TA-Ce treatment group, the DTP-LSA@TC NPs treatment group presented stronger red fluorescence and weaker green fluorescence, whereas compared with the MDI treatment group, the DTP-LSA@MDI NPs treatment group presented stronger red fluorescence and weaker green fluorescence. These results preliminarily confirm that both MDI and TA-Ce have significant mitochondrial protective effects and that liposome encapsulation further increases the therapeutic efficacy of these drugs (Fig. 4c–e). We also utilized the calcein-cobalt quenching method combined with CLSM observation and quantitative flow cytometry to evaluate the opening of the mitochondrial permeability transition pore (mPTP). Calcein retained in the mitochondrial matrix emits green fluorescence, and its intensity is inversely proportional to the degree of mPTP opening. Treatment with Lonomycin is the positive control group, which causes the cells to load more Ca2+, activates the mitochondrial permeability transition pore and causes mitochondrial fluorescence quenching. (Fig. 4g). CLSM observations showed that the green fluorescence intensity of cells in the LPS-induced group was significantly reduced, indicating continuous mPTP opening. The quantitative flow cytometry results were consistent with these findings (Fig. 4h–j). In contrast, the DTP-LSA@MTC NPs treatment group had the strongest green fluorescence, indicating that this treatment most effectively inhibited LPS-induced abnormal mPTP opening. The fluorescence intensities of the DTP-LSA@TC NP- and DTP-LSA@MDI NP-treated groups were significantly higher than those of the corresponding free drug-treated groups (TA-Ce and MDI), further confirming that liposome encapsulation increases the ability of drugs to stabilize the mPTP. Abnormal mPTP opening is a key cause of ΔΨm collapse. Subsequently, we detected key indicators of mitochondrial bioenergetics, including oxygen consumption rate (OCR) and ATP production capacity. As the core organelle responsible for energy metabolism, damaged mitochondria undergo marked suppression of aerobic respiration, which further leads to insufficient ATP generation, representing a critical pathological event downstream of cellular oxidative stress injury. In this study, cells in the injury model group exhibited obvious inhibition of respiratory function and impaired energy synthesis. In contrast, treatment with DTP-LSA@MTC NPs notably reversed these pathological alterations and effectively restored cellular OCR and ATP production levels, with superior protective effects compared with free drug intervention. These findings further verify that DTP-LSA@MTC NPs can comprehensively ameliorate the functional status of impaired mitochondria via regulating oxidative stress and energy metabolism, thereby providing sufficient energy supply for cells (Fig. S7). Thus, the experimental results are highly consistent with those of the JC-1 assay. These results directly confirm the excellent ability of DTP-LSA@MTC NPs to restore mitochondrial energy production. Mitochondrial dysfunction (including dissipation of mitochondrial membrane potential (ΔΨm), abnormal opening of mitochondrial permeability transition pore (mPTP), impaired aerobic respiration, and insufficient ATP synthesis) and ROS bursts are key pathways that induce apoptosis. We quantitatively detected the apoptosis rate using Annexin V-FITC/propidium iodide (PI) double-staining and flow cytometry. The results showed that LPS stimulation significantly induced HPMEC apoptosis, with the highest total apoptosis rate. All drug treatments effectively reduced the apoptosis rate; the DTP-LSA@MTC NPs treatment group had the lowest apoptosis rate, indicating the most significant protective effect. The apoptosis rates of the DTP-LSA@TC NPs and DTP-LSA@MDI NPs treatment groups were also significantly lower than those of the corresponding free drug treatment groups (TA-Ce and MDI), indicating that the liposome delivery system substantially improved the antiapoptotic efficacy of the drugs (Fig. 4d). DTP-LSA@MTC NPs exhibited excellent mitochondrial-protective effects in all aspects (Fig. 4f).Fig. 4In vitro therapeutic effects of DTP-LSA@MTC NPs. (a) Fluorescence images and (b) quantitative analysis from the JC-1 assay assessing mitochondrial membrane depolarization in LPS-stimulated HPMEC cells after different treatments, scale bars: 30 μm, n = 3. The lower-left quadrant (FITC-A-PI-) indicates viable cells; the lower-right quadrant (FITC-A+PI−) indicates early apoptotic cells; the upper-right quadrant (FITC-A+PI+) indicates late apoptotic/necrotic cells. (c) Quantitative analysis and (e) Flow cytometry of the JC-1 assay to measure mitochondrial membrane depolarization in LPS-stimulated HPMEC cells after different treatments, n = 3, FITC: the fluorescence intensity of JC-1 monomers, PE: the fluorescence intensity of JC-1 aggregates. (d) Quantitative analysis and (f) chart of flow cytometry results for apoptosis assay of LPS-stimulated HPMEC cells after different treatments, n = 3. (g) Fluorescence images and (j) corresponding fluorescence intensity for mPTP permeability detection in LPS-stimulated HPMEC cells incubated with different treatments. scale bars: 50 μm, n = 3. (h-i) Chart and quantitative analysis of flow cytometry results for mPTP permeability detection in LPS-stimulated HPMEC cells incubated with different treatments, n = 3. (k) Western blot showing expression levels of NLRP3, C-Casp1, HK1, and P-Drp1 after different treatments in HPMEC cells. Quantitative analysis of the relative gray values for (l) NLRP3, (m) C-Casp1, (n) HK1, and (o) P-Drp1 after different treatments in HPMEC cells, n = 3. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. In vitro therapeutic effects of DTP-LSA@MTC NPs. (a) Fluorescence images and (b) quantitative analysis from the JC-1 assay assessing mitochondrial membrane depolarization in LPS-stimulated HPMEC cells after different treatments, scale bars: 30 μm, n = 3. The lower-left quadrant (FITC-A-PI-) indicates viable cells; the lower-right quadrant (FITC-A+PI−) indicates early apoptotic cells; the upper-right quadrant (FITC-A+PI+) indicates late apoptotic/necrotic cells. (c) Quantitative analysis and (e) Flow cytometry of the JC-1 assay to measure mitochondrial membrane depolarization in LPS-stimulated HPMEC cells after different treatments, n = 3, FITC: the fluorescence intensity of JC-1 monomers, PE: the fluorescence intensity of JC-1 aggregates. (d) Quantitative analysis and (f) chart of flow cytometry results for apoptosis assay of LPS-stimulated HPMEC cells after different treatments, n = 3. (g) Fluorescence images and (j) corresponding fluorescence intensity for mPTP permeability detection in LPS-stimulated HPMEC cells incubated with different treatments. scale bars: 50 μm, n = 3. (h-i) Chart and quantitative analysis of flow cytometry results for mPTP permeability detection in LPS-stimulated HPMEC cells incubated with different treatments, n = 3. (k) Western blot showing expression levels of NLRP3, C-Casp1, HK1, and P-Drp1 after different treatments in HPMEC cells. Quantitative analysis of the relative gray values for (l) NLRP3, (m) C-Casp1, (n) HK1, and (o) P-Drp1 after different treatments in HPMEC cells, n = 3. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Western blot (WB) analysis was performed to determine whether these therapeutic agents modulate protein expression profiles at the cellular level. The results showed that DTP-LSA@MTC NPs significantly attenuated phosphorylated Drp1 (p-Drp1) levels, reduced caspase-1 activation, and decreased NLRP3 inflammasome expression. Moreover, compared with their respective free drug control groups, the liposome-encapsulated MDI and TA-Ce groups exhibited superior inhibitory effects. These data suggest that DTP-LSA@MTC NPs suppress the inflammasome and attenuate cytokine storms in vitro via the Drp1–HK1–NLRP3 axis. According to the results of mitochondrial functional assays, compared with MDI, TA-Ce displayed greater mitochondrial protection; however, the functional performance of DTP-LSA@MDI NPs surpassed that of DTP-LSA@TC NPs. Notably, DTP-LSA@MTC NPs, which combine TA-Ce and MDI, achieved optimal therapeutic outcomes, reinforcing their potential as advanced nanodrug agents to increase mitochondrial resilience and reduce the oxidative burden (Fig. 4k–o). In vivo targeting efficacy and safety of DTP-LSA@MTC NPs We assessed the lung inflammation-specific targeting capacity of DiR-DTP-LSA@MTC NPs in vivo using a fluorescence imaging system to systematically monitor NP biodistribution in major organs following intravenous (IV) administration. The fluorescence intensity in all the groups peaked at 24 h post-injection. Compared with the non-ARDS group, the ARDS group exhibited a significantly higher pulmonary fluorescence intensity, and the groups treated with formulations containing the LSA peptide presented markedly stronger fluorescence signals than those lacking it. These results suggest that both the ARDS-associated inflammatory microenvironment and the presence of the targeting LSA peptide synergistically increase nanoparticle accumulation in lung tissue. Strikingly, the lung-targeting efficacy of the DiR-DTP-LSA@MTC NPs in the ARDS group was the most pronounced, with the fluorescence intensity substantially exceeding that in all the other groups, confirming the superior targeting ability under ARDS conditions. Even in the absence of ARDS, DiR-DTP-LSA@MTC NPs maintained notable pulmonary targeting, underscoring the critical role of the LSA peptide in directing NPs to the lung. In contrast, compared with the LSA peptide-modified formulations, the DiR-DP@MTC NPs exhibited a lower fluorescence intensity at all time points, which is consistent with the results of the cellular uptake experiments and further confirms the targeting contribution of the peptide. For a comprehensive organ distribution profile, the animals were sacrificed at 24 h for ex vivo fluorescence imaging, revealing high NP accumulation in the liver and spleen—likely attributable to the clearance functions of the reticuloendothelial system (RES). Nevertheless, compared with that in non-RES organs, lung fluorescence in the ARDS and LSA peptide-containing groups remained significantly elevated, reinforcing the in vivo findings. Collectively, these results indicate that DTP-LSA@MTC NPs, guided by the LSA peptide, achieve efficient and targeted lung delivery, increase the local drug concentration and represent a precise therapeutic strategy for ARDS. This work provides a robust experimental foundation for the clinical translation of targeted nanomedicines in inflammatory lung diseases (Fig. 5b–d). Next, we conducted a series of biochemical, hematological, and histopathological assessments to rigorously evaluate the in vivo safety profile of DTP-LSA@MTC NPs. Following IV administration at defined time points, key blood biochemical markers for hepatic and renal function—alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (Cr)—alongside complete blood count parameters (white blood cell, red blood cell, and platelet counts) were measured. At study termination, the mice were euthanized, and major organs (heart, liver, spleen, lung, and kidney) were processed for hematoxylin and eosin (H&E) staining to detect pathological changes. The histopathological examination corroborated these findings, revealing no overt structural or inflammatory abnormalities in any organ within the DTP-LSA@MTC NP-treated cohort (Fig. 5e). At all time points, the biochemical and hematologic indices remained within normal ranges, and no evidence of liver, kidney, or bone marrow dysfunction was observed at the tested dosage, indicating the absence of detectable systemic toxicity (Fig. 5f). These data confirm the favorable biocompatibility of DTP-LSA@MTC NPs and support their safe application under the evaluated experimental conditions, providing essential toxicological evidence for future clinical translation.Fig. 5In vivo lung-targeting efficacy and biosafety evaluation of DTP-LSA@MTC NPs. (a) Schematic illustration of the experimental design and treatment schedule in the mice. (b) In vivo fluorescence images and (c) corresponding fluorescence intensity in the lungs at different time points after intravenous injection with DiR-labeled DTP-LSA@MTC NPs or DP@MTC NPs, with or without ARDS induction, n = 5. (d) Ex vivo fluorescence intensity of DTP-LSA@MTC NPs or DP@MTC NPs in the main organs at 24 h post-injection. (e) H&E staining and (f) blood biochemistry and whole blood analysis of the main organs after intravenous injection of DTP-LSA@MTC NPs at predetermined time points (1, 3, 7, 14, and 28 days) in mice, scale bars: 50 μm. (g) Survival rate of ARDS model mice with different treatments, n = 5. (h) Lung W/D ratio and (i) MPO activity in each group of mice, n = 5. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. In vivo lung-targeting efficacy and biosafety evaluation of DTP-LSA@MTC NPs. (a) Schematic illustration of the experimental design and treatment schedule in the mice. (b) In vivo fluorescence images and (c) corresponding fluorescence intensity in the lungs at different time points after intravenous injection with DiR-labeled DTP-LSA@MTC NPs or DP@MTC NPs, with or without ARDS induction, n = 5. (d) Ex vivo fluorescence intensity of DTP-LSA@MTC NPs or DP@MTC NPs in the main organs at 24 h post-injection. (e) H&E staining and (f) blood biochemistry and whole blood analysis of the main organs after intravenous injection of DTP-LSA@MTC NPs at predetermined time points (1, 3, 7, 14, and 28 days) in mice, scale bars: 50 μm. (g) Survival rate of ARDS model mice with different treatments, n = 5. (h) Lung W/D ratio and (i) MPO activity in each group of mice, n = 5. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. To investigate the in vivo pharmacokinetics and tissue distribution of Ce, serum samples were collected at predetermined time points following intravenous administration of DTP-LSA@MTC NPs. All three C57BL/6 mice (A, B, and C) exhibited a rapid decline in serum Ce levels within the first 12 h post-injection, indicating a fast initial distribution phase. Specifically, serum Ce concentrations peaked immediately after administration and then decreased sharply over time. By 48 h, serum Ce levels in all animals had dropped to approximately 25–40 μg/L, representing a significant reduction from the initial peak values (140–175 μg/L). Notably, although some inter-individual variability in peak concentrations was observed among the three mice, the overall elimination trend was consistent across all subjects: serum Ce concentrations gradually decreased throughout the 48-h observation period, with a slower elimination phase becoming evident after 12 h. These results demonstrate that cerium derived from DTP-LSA@MTC NPs achieves rapid in vivo distribution and gradual elimination. No abnormal accumulation was observed in systemic circulation within 48 h (Fig. S9A). We further investigated the in vivo tissue distribution of Ce derived from DTP-LSA@MTC NPs by measuring Ce levels in major organs at 1 and 14 days post-intravenous administration (Fig. S9B). At day 1 post-injection, the highest Ce accumulation was observed in the liver, followed by the spleen, which is consistent with the typical biodistribution pattern of intravenously administered nanoparticles sequestered by the mononuclear phagocyte system (MPS). Notably, significant Ce deposition was also detected in the lungs, confirming effective delivery of the LSA peptide-modified nanoplatform to the target pulmonary tissue. In contrast, relatively low Ce levels were observed in the heart and kidney. At day 14 post-administration, Ce concentrations in all organs were markedly reduced compared with the day 1 time point. Specifically, Ce levels in the liver and spleen decreased significantly, and only trace amounts of Ce remained in the lung, heart, and kidney tissues. These results indicate that the accumulated Ce-containing nanoparticles are gradually cleared from the body over time, with no evidence of persistent or excessive long-term accumulation in major organs. Collectively, these tissue distribution data demonstrate that DTP-LSA@MTC NPs exhibit favorable in vivo biodistribution, with targeted accumulation in the lung at the early stage and efficient systemic clearance within 14 days, supporting the safety and clinical translational potential of the nanoplatform. Therapeutic efficacy of DTP-LSA@MTC NPs Considering the excellent lung-targeting capability of the LSA peptide and the mitochondrial-protective and anti-inflammatory properties of MDI and TA-Ce, a series of in vivo experiments was conducted to evaluate their therapeutic efficacy. Various drug formulations were administered to lipopolysaccharide (LPS)-induced ARDS model mice. The overall experimental workflow, including detailed procedures for model establishment, drug administration, and sample collection, is shown in Fig. 5a. Specifically, after the intratracheal instillation of 20 mg/kg LPS in C57BL/6 mice, 30 mg/kg MDI was immediately administered via intraperitoneal injection, whereas DTP-LSA@MDI NPs and DTP-LSA@MTC NPs (each containing 30 mg/kg MDI) were injected intravenously. The survival curves show the five-day survival outcomes among the different groups. The survival rates gradually decreased in the LPS and DP NP groups because of uncontrolled inflammatory cytokine storms, whereas the survival rates markedly improved in the groups treated with drug-loaded nanoparticles (Fig. 5g). Following inflammatory injury, severe pulmonary edema typically develops, accompanied by elevated alveolar protein concentrations due to capillary damage. The lung wet/dry (W/D) ratio was assessed to determine the water content and indirectly evaluate the severity of edema. As expected, a significantly increased W/D ratio (Fig. 5h) and protein concentration (Fig. S8A) in the BALF were observed in the LPS group. Treatment with DTP-LSA NPs, MDI, DTP-LSA@MDI NPs, or DTP-LSA@MTC NPs effectively alleviated pulmonary edema and reduced vascular permeability caused by inflammation. Since the LSA peptide competitively inhibits the DPEP1 receptor, which is involved in neutrophil adhesion, To explore whether LSA peptide can reduce inflammation by inhibiting neutrophil aggregation, we used the following indicators to verify. Myeloperoxidase (MPO) is the functional and activation marker of neutrophil. Its main function is to kill microorganisms in phagocytes, use hydrogen peroxide and chloride ions to produce hypochlorite, and form free radicals with oxidative capacity, the changes of its level and activity represent the function and activity state of neutrophil. MPO assays showed significantly lower MPO expression in the DTP-LSA NP group than that in the LPS and DP NP groups, which is consistent with the results observed in the MDI and lipid nanoparticle treatment groups (Fig. 5i). Immunofluorescence staining was performed to visualize the distribution of Ly6G (a neutrophil marker, red fluorescence) in lung tissues. In the LPS and DP NP groups, severe inflammatory cell infiltration and thickened alveolar septa were observed, whereas markedly fewer inflammatory cells and a preserved alveolar structure were detected in the group treated with DTP-LSA@MTC NPs, confirming their potent anti-inflammatory efficacy (Fig. 6b). Collectively, these findings indicate that the synergistic actions of MDI, TA-Ce, and the LSA peptide effectively reduce neutrophil infiltration, mitigate inflammation, and protect pulmonary tissue. This improvement can be attributed to the precise pulmonary targeting mediated by the LSA peptide and the subsequent attenuation of inflammatory responses through the competitive inhibition of neutrophil aggregation. This study provides a critical experimental foundation for the development of efficient nanotherapeutics for ARDS and highlights a promising new direction for leveraging the LSA peptide in the treatment of inflammatory diseases.Fig. 6Inhibitory effects of DTP-LSA@MTC NPs on inflammatory and mitochondria-related proteins. (a) Representative H&E staining of lung tissues; the lower panels indicate high-resolution images, scale bar: 50 μm, n = 5. (b-d) Immunofluorescence images of Ly6G, p-Drp1, C-Cas1, and NLRP3 in the lung tissue sections, scale bars: 50 μm, n = 5. (e-h) Quantitative analysis of fluorescence intensity for Ly6G, p-Drp1, C-Cas1, and NLRP3, n = 5. (i, k) IL-1β and IL-18 levels in lung tissues and in (j, l) BALF, n = 5. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Inhibitory effects of DTP-LSA@MTC NPs on inflammatory and mitochondria-related proteins. (a) Representative H&E staining of lung tissues; the lower panels indicate high-resolution images, scale bar: 50 μm, n = 5. (b-d) Immunofluorescence images of Ly6G, p-Drp1, C-Cas1, and NLRP3 in the lung tissue sections, scale bars: 50 μm, n = 5. (e-h) Quantitative analysis of fluorescence intensity for Ly6G, p-Drp1, C-Cas1, and NLRP3, n = 5. (i, k) IL-1β and IL-18 levels in lung tissues and in (j, l) BALF, n = 5. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. Mechanism by which MDI inhibits inflammation MDI is a selective inhibitor of Drp1 and is known to suppress Drp1-mediated mitochondrial fission, thereby inhibiting NLRP3 inflammasome activation and reducing inflammatory mediator release to mitigate inflammation. To elucidate the mechanism by which DTP-LSA@MTC NPs alleviate pulmonary inflammation in ARDS mice, immunofluorescence analyses were performed to detect p-Drp1, NLRP3, and C-Caspase-1 levels. Compared with the free MDI, both DTP-LSA@MDI NPs and DTP-LSA@MTC NPs significantly reduced p-Drp1 (Fig. 6c), NLRP3, and C-Caspase-1 (Fig. 6d) levels in lung tissues, indicating increased anti-inflammatory efficacy(Fig. 6f–h). Moreover, the expression of inflammatory cytokines such as IL-1β (Fig. 6i and j), IL-18 (Fig. 6k and l), and IL-6 (Fig. S8B–C) was markedly downregulated in both lung tissue and bronchoalveolar lavage fluid (BALF), confirming the anti-inflammatory efficacy of the nanoparticles. Importantly, compared with free MDI, DTP-LSA@MDI NPs and DTP-LSA@MTC NPs resulted in superior therapeutic outcomes, underscoring their increased bioactivity and targeted drug delivery. Furthermore, flow cytometry was used to quantify neutrophils in lung tissue and BALF. Compared with the DP NP group, the DTP-LSA NP group exhibited a marked reduction in the proportion of neutrophils in both lung tissue and BALF. Similarly, the MDI group also presented decreased neutrophil counts because the inflammatory response was mitigated, although the inhibition of neutrophil aggregation by the LSA peptide was more pronounced. Compared with free MDI, both DTP-LSA@MDI NPs and DTP-LSA@MTC NPs exhibited superior efficacy that was attributable not only to increased pulmonary drug accumulation via targeted nanoparticle delivery but also to the direct modulation of neutrophil aggregation by the LSA peptide (Fig. 7a–c). In summary, DTP-LSA@MTC NPs substantially increased the therapeutic efficacy of MDI and suppressed cytokine release and inflammatory cascades. Western blot (WB) analysis was performed to further verify these molecular mechanisms. Under physiological conditions, HK1 binds to VDAC to maintain mitochondrial stability, whereas the inflammatory activation of p-Drp1 promotes HK1 dissociation from VDAC, leading to mitochondrial dysfunction and inflammation. Our results indicated that DTP-LSA@MTC NP treatment significantly decreased p-Drp1 levels, inhibited HK1 dissociation, and reduced NLRP3 and Caspase-1 activation. Collectively, these data indicate that DTP-LSA@MTC NPs inhibit Drp1 phosphorylation, prevent excessive mitochondrial fragmentation, and consequently suppress NLRP3 inflammasome activation and the cytokine storm (Fig. 7d–i).Fig. 7In vivo therapeutic effect of DTP-LSA@MTC NPs. (a) Chart of flow cytometry of neutrophils in lung tissue and BALF after different treatments. Quantitative analysis of neutrophils in (b) lung tissue and (c) BALF, n = 5. (d-i) Quantitative analysis of NLRP3, HK1, VDAC1, C-Casp1, and P-Drp1 expression from western blotting data, n = 3. (j) Heatmap of the DEGs; genes related to inflammation and mitochondrial function are indicated in red boxes. (k) GSEA analysis of inflammatory response in the LPS and LPS + DTP-LSA@MTC NPs groups. (l) Volcano plot comparing gene expression between LPS and LPS + DTP-LSA@MTC NPs groups. (m,n) GO and KEGG pathway enrichment analysis of DEGs identified in the comparison between LPS and LPS + DTP-LSA@MTC NPs groups. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) In vivo therapeutic effect of DTP-LSA@MTC NPs. (a) Chart of flow cytometry of neutrophils in lung tissue and BALF after different treatments. Quantitative analysis of neutrophils in (b) lung tissue and (c) BALF, n = 5. (d-i) Quantitative analysis of NLRP3, HK1, VDAC1, C-Casp1, and P-Drp1 expression from western blotting data, n = 3. (j) Heatmap of the DEGs; genes related to inflammation and mitochondrial function are indicated in red boxes. (k) GSEA analysis of inflammatory response in the LPS and LPS + DTP-LSA@MTC NPs groups. (l) Volcano plot comparing gene expression between LPS and LPS + DTP-LSA@MTC NPs groups. (m,n) GO and KEGG pathway enrichment analysis of DEGs identified in the comparison between LPS and LPS + DTP-LSA@MTC NPs groups. Data are expressed as mean ± SD. The statistical significance levels were denoted as ∗ P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Furthermore, RNA sequencing (RNA-seq) was performed to identify differentially expressed genes (DEGs) between the LPS and DTP-LSA@MTC NP groups, with a focus on pathways associated with pulmonary vascular endothelial function (Fig. 7j). The principal component analysis (PCA) results indicated a clear separation among different sample groups (Fig. S10). Gene set enrichment analysis (GSEA) was conducted to explore the functional changes in key biological pathways regulated by the intervention drug. The results revealed significant differences in the enrichment patterns of the two crucial pathways between the two groups, which collectively illustrate the regulatory role of DTP-LSA@MTC NPs in LPS-induced lung tissue injury. GSEA revealed a significant decrease in the enrichment of the “inflammatory response” pathway, a core cascade in LPS-induced lung pathology, in the DTP-LSA@MTC NP group relative to that in the LPS group (p.adjust = 0.1065, p value = 0.003613). This robust statistical significance indicated that the drug strongly inhibited the hyperactive inflammatory response in LPS-injured lung tissue (Fig. 7k). ATP is the core energy source of cells, and its generation directly affects the metabolic activity and functional maintenance of lung tissue cells. The GSEA results revealed that the “ATP generation from ADP” pathway was significantly upregulated in the DTP-LSA@MTC NPs group compared with the LPS group (p.adjust = 0.2433, p value = 0.04135) (Fig. S11). The volcano plot shows significant changes in gene expression, including the downregulation of NLRP3 (Fig. 7l). The Gene Ontology (GO) analysis revealed substantial alterations in biological processes related to inflammation (Fig. 7m), whereas Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis indicated that the DEGs were predominantly involved in inflammatory signaling pathways such as JAK–STAT and NF-κB signaling (Fig. 7n). Integrating the above findings, we conclude that while DTP-LSA NPs exert evident anti-inflammatory effects, particularly by inhibiting neutrophil aggregation, their ability to attenuate inflammation by regulating mitochondrial fission remains limited. However, the DTP-LSA@MTC NPs engineered in this study effectively controlled excessive mitochondrial fission by suppressing Drp1 phosphorylation, thereby restraining cytokine storm development and representing a novel strategy for ARDS therapy. This research not only bridges a critical gap in ARDS pharmacotherapy but also provides a strong theoretical foundation and experimental evidence supporting the design of next-generation anti-inflammatory nanomedicines that protect the mitochondria. Discussion Significant progress has been made in the development of nanotherapeutics for acute respiratory distress syndrome (ARDS) in recent years. In contrast to prior approaches, our DTP-LSA@MTC NPs are rationally engineered to concurrently deliver therapeutic payloads to inflamed lung tissue (via LSA peptides) and mitochondrial compartments (via tannic acid, TA), thereby synergistically modulating dysregulated inflammatory responses and mitochondrial oxidative stress. To date, dual-targeted strategies for ARDS remain underexplored. Nevertheless, this study has several limitations. First, DPEP1 was identified as a candidate receptor mediating LSA peptide–dependent lung tropism. Although the interaction between DPEP1 and LSA peptide has been reported in previous literature, further validation using gene-deficient cell models was not performed in this study. Existing chemical inhibitors targeting DPEP1 primarily regulate its catalytic activity and exert negligible effects on its membrane adhesion property, making them inappropriate for verifying the binding specificity of peptide–receptor interactions. Consequently, the current study only provides correlative evidence rather than definitive causal validation for this targeting interaction. In addition, restricted by the available experimental equipment, we were unable to determine the PaO2/FiO2 ratio, lung compliance, and other respiratory mechanics parameters in animal models. Consistent with most previously published preclinical ARDS studies, our therapeutic efficacy evaluation mainly relied on lung histopathological observation and inflammatory response analysis. Although these approaches can preliminarily reflect therapeutic outcomes, they do not fully meet the comprehensive clinical evaluation criteria for ARDS. Future studies will address these limitations by employing DPEP1 gene-deficient models to confirm peptide-receptor binding specificity and upgrading experimental equipment to assess key respiratory mechanics parameters, thereby enhancing the clinical translatability of the DTP-LSA@MTC NPs nanoplatform for ARDS treatment. Conclusions In this study, we engineered DTP-LSA@MTC NPs, a novel nanotherapeutic platform that integrates the Drp1 inhibitor Mdivi-1 with the TA-Ce nanozyme. This system uniquely accomplishes multilevel targeting, specifically homing to the inflamed pulmonary endothelium via the LSA peptide and subsequently localizing to mitochondria via TA. By simultaneously inhibiting pathological Drp1 phosphorylation, scavenging ROS with multienzyme-mimetic activity, and competitively inhibiting neutrophil recruitment, DTP-LSA@MTC NPs effectively disrupt the vicious cycle between mitochondrial oxidative dysfunction and NLRP3 inflammasome activation in individuals with ARDS. This innovative strategy not only clarifies critical pathogenic mechanisms underlying ARDS but also represents a generalized and adaptable approach for targeted nanomedicine, highlighting its significant clinical relevance and promise for future application in critical care settings. Experimental section Materials Dipalmitoylphosphatidylglycerol (DPPG), dipalmitoylphosphatidylcholine (DPPC), and cholesterol were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Acetone, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), PEG2000, and LSA peptide were synthesized by RuixiBio Co., Ltd. (Xi'an, China). Primary antibodies against NLRP3, cleaved caspase-1 (C-Caspase1), phosphorylated dynamin-related protein 1 (p-Drp1), hexokinase 1 (HK1), and voltage-dependent anion-selective channel 1 (VDAC1) for Western blot (WB) analysis were purchased from a supplier in Hangzhou, China. Mdivi-1 (MDI) and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) were purchased from Glpbio Technology Co., Ltd. (California, USA). Lipopolysaccharide (LPS; Escherichia coli, serotype O55:B5), tannic acid (TA), and Ce sulfate [Ce(SO4)2] were purchased from Sigma-Aldrich (St. Louis, MO, USA). ELISA kits for IL-1β, IL-6, and IL-18 were supplied by Quanzhou Jiubang Biotechnology Co., Ltd. (Quanzhou, China). The JC-1 mitochondrial membrane potential kit was obtained from a supplier in Shanghai, China, and the mPTP assay kit, the mtROS assay kit, the ATP assay kit was purchased from Abbkine Scientific Co., Ltd. (Wuhan, China). The OCR assay kit was purchased from Elabscience Biotechnology Co.,Ltd. (Wuhan, China). Synthesis of TA-Ce TA-Ce complex was synthesized as follows: tannic acid (TA; 40.8 mg) was dissolved in 1 mL of phosphate-buffered saline (PBS), while cerium sulfate [Ce(SO4)2; 8 mg] was dissolved in 2% sulfuric acid to prepare a cerium sulfate solution. Subsequently, 100 μL of the TA solution (24 mM) was added to 600 μL of the Ce(SO4)2 solution (24 mM), and the pH was adjusted to approximately 5.0 using sodium hydroxide (NaOH). The resulting mixture was transferred into a dialysis bag with a molecular weight cutoff of 3 kDa and dialyzed against distilled water for 48 h, with the external medium replaced every 6 h. The final TA-Ce complex solution was obtained at a concentration of 7.8 mg/mL. Synthesis of lipid films For lipid film preparation, DPPG (1.5 mg), cholesterol (1.5 mg), DPPC (5 mg), DSPE-TK-PEG2000-LSA peptide (2 mg), and MDI (5 mg) were dissolved in chloroform with ultrasonic assistance to ensure complete dissolution. The resulting solution was evaporated under reduced pressure using a rotary evaporator for 1 h to form a uniform lipid film. The lipid film was then hydrated with 4 mL of deionized water; for the DTP-LSA@TC NPs and DTP-LSA@MTC NPs formulations, 3 mL was used, yielding a lipid suspension. Preparation of DTP-LSA@MTC NPs The morphology of DTP-LSA@MTC NPs was examined by transmission electron microscopy (TEM; FEI TECNAI G2 12, Thermo Fisher Scientific). Particle size distribution and zeta potential of DTP-LSA NPs, DTP-LSA@TC NPs, DTP-LSA@MDI NPs, and DTP-LSA@MTC NPs were measured using dynamic light scattering (DLS) with a Malvern Zetasizer Nano Series instrument (UK). The cerium content in the TA-Ce complex was quantified via inductively coupled plasma optical emission spectrometry (ICP-OES; Thermo ICPOES7200, USA). Elemental composition and atomic ratios were analyzed by X-ray photoelectron spectroscopy (XPS; Thermo Escalab 250XI). UV-visible spectroscopy was employed to construct standard calibration curves for the quantification of MDI and the TA-Ce complex. Liposomes were collected by centrifugation at 12,000 rpm and 4 °C for 20 min. The liposomal membrane was subsequently disrupted with methanol, and the concentration of MDI in the resulting supernatant was determined spectrophotometrically. Encapsulation efficiency (EE%) and loading efficiency (LE%) were calculated according to the following equations: EE% = (mass of encapsulated MDI/total mass of MDI added) × 100%; LE% = (mass of encapsulated MDI/total mass of nanoparticles) × 100%. These parameters provided a quantitative evaluation of the drug encapsulation and loading capacity of the nanoparticle system. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay was employed to assess the reactive oxygen species (ROS) scavenging performance of the samples. Briefly, 2 mL of each sample combined with 2 mL of 0.2 mM DPPH solution was prepared in absolute ethanol, and the mixture was incubated in the dark for 30 min. The blank group contained 2 mL of 95% ethanol and 2 mL of DPPH solution. Absorbance values of the blank (Ac), sample (Ai), and control (Aj) groups were measured at 517 nm. The radical scavenging activity was calculated using the following formula: Scavenging rate (%) = [1 - (Ai - Aj)/Ac] × 100%. To further evaluate the reactive oxygen species (ROS)-responsive drug release behavior of the nanoparticles, DTP-LSA@MTC NPs were incubated with double-distilled water, 100 μM H2O2, or 200 μM H2O2 under continuous stirring. At predetermined time points (0, 2, 4, 8, 24, 48, and 72 h), intact liposomes were collected by centrifugation, dissolved in methanol, and the MDI content was quantified spectrophotometrically [40]. The content of Ce element in the collected supernatant was quantified by inductively coupled plasma (ICP) spectroscopy. Based on the measured Ce element content in the supernatant, the cumulative drug release percentage of TA-Ce at different time points was calculated using the following formula: Cumulative release (%) = (Ce content in supernatant at each time point/Total Ce content in DTP-LSA@MTC NPs) × 100%, to comprehensively assess the ROS-responsive release behavior of both TA-Ce and MDI from the nanoparticles. Cell culture and therapeutic assays Human pulmonary microvascular endothelial cells (HPMECs) were cultured in endothelial cell medium supplemented with 5% fetal bovine serum (FBS), 1% endothelial cell growth supplement, 1% penicillin/streptomycin, and maintained at 37 °C in a humidified incubator containing 5% CO2. Human umbilical vein endothelial cells (HUVECs) were propagated in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin under identical culture conditions [40]. To evaluate cellular uptake, HPMECs and HUVECs (2.5 × 105 cells/well) were seeded in confocal dishes and subjected to inflammatory induction. Then, HPMECs and HUVECs were co-incubated with Dil-labeled DTP-LSA@MTC NPs and DP@MTC NPs. At 0.5, 1, 2, and 4 h post-incubation, nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI), and nanoparticle internalization was visualized by CLSM. Following replicate experiments, cells were harvested for flow cytometry analysis, and fluorescence intensity was quantified using the PE-A channel. To evaluate mitochondrial targeting, FITC-labeled TA-Ce complexes and DTP-LSA@MTC NPs were added to pre-seeded HPMECs and HUVECs. After 24 h, mitochondria were stained with MitoTracker Deep Red 633, and the colocalization ratio between red (mitochondrial) and green (FITC-labeled nanoparticle) fluorescence signals was analyzed by CLSM. For cytotoxicity assessment, HPMECs were seeded in 96-well plates at a density of 1 × 105 cells/well and treated with varying concentrations of MDI, TA-Ce complex, DTP-LSA@TC NPs, DTP-LSA@MDI NPs, or DTP-LSA@MTC NPs. After 24 h, cell viability was determined using the Cell Counting Kit-8 (CCK-8) assay. For assays assessing mitochondrial membrane potential (JC-1), reactive oxygen species (ROS), mitochondrial permeability transition pore (mPTP), and apoptosis, HPMECs were seeded in confocal dishes or 6-well plates at a density of 2.5 × 106 cells/well. Cells were first stimulated with 4 μg/mL lipopolysaccharide (LPS) for 4 h, followed by exposure to 20 μM nigericin (Nig) for 1 h. Subsequently, cells were treated with 10 μg/mL MDI, 12 μg/mL TA-Ce complex, or equivalent concentrations of DTP-LSA@TC NPs, DTP-LSA@MDI NPs, or DTP-LSA@MTC NPs for 12 h. For flow cytometry analysis, cells were collected by centrifugation and washed with buffer; for fluorescence imaging, cells were fixed, nuclei were stained with DAPI, and samples were mounted for CLSM observation. For the transwell migration assay, HPMEC were seeded onto the upper surface of 8.0 μm pore-size transwell inserts and cultured to form a confluent monolayer. Inflammatory chemokines were added to the lower chamber. Neutrophils were preincubated with different nanoparticle preparations (DP@MTC, DTP-LSA@MTC) for 30 min at 37 °C, and then added to the upper chamber. After incubation at 37 °C for 2 h to allow migration, non-migrated cells on the upper surface were removed, and migrated neutrophils in the lower chamber were collected, washed with cold PBS, stained with an APC-conjugated anti-Ly6G antibody for 20 min at 4 °C in the dark, and analyzed by flow cytometry to quantify the number of Ly6G-positive migrated cells and calculate the migration rate. Animal experiments Male C57BL/6 mice (5 weeks old) were purchased from Hunan Slack Kingda Laboratory Animal Co., Ltd. and housed under specific pathogen-free (SPF) conditions with free access to standard chow and water. All experimental procedures involving animals were conducted in accordance with the ethical guidelines approved by Chongqing Medical University. To evaluate the therapeutic efficacy of various treatment regimens in a murine model of ARDS, mice were randomly assigned to six groups (n = 5 per group): (A) LPS group, (B) DP NPs + LPS group, (C) DTP-LSA NPs + LPS group, (D) MDI (Mdivi-1) + LPS group, (E) DTP-LSA@MDI NPs + LPS group, and (F) DTP-LSA@MTC NPs + LPS group. After anesthesia with sodium pentobarbital (50 mg/kg, intraperitoneal injection [ip]), mice received an intratracheal instillation of LPS (20 mg/kg). Immediately thereafter, MDI (30 mg/kg, dissolved in a vehicle consisting of DMSO, PEG400, Tween-80, and normal saline) was administered via intraperitoneal injection. The nanoparticle formulations were centrifuged at 12,000 rpm for 20 min, resuspended to achieve an MDI concentration of 6 mg/mL, and injected via the tail vein. Twenty-four hours post-treatment, mice were euthanized by exsanguination under deep anesthesia, and bronchoalveolar lavage fluid (BALF) as well as lung tissue samples were collected. Lung injury severity was histologically assessed, and cytokine levels in BALF were quantified. For each group, the lung wet-to-dry (W/D) ratio, BALF protein concentration, and myeloperoxidase (MPO) activity were measured. Additionally, survival rates following different treatment protocols were recorded over time. Neutrophil assays To quantify the proportion of neutrophils in BALF, the collected BALF samples were centrifuged at 1200 rpm at 4 °C for 5 min. The resulting pellet was retained, and each sample was incubated with the following antibodies: anti-CD45-APC/Cyanine7, anti-CD19-PE, anti-CD3-FITC, anti-CD11b-APC, and anti-Ly6G-PE/Cyanine7, for 20 min at room temperature in the dark. Following incubation, cells were washed with PBS, centrifuged again at 1200 rpm for 5 min, and the pellet was resuspended in 200 μL of PBS. Neutrophil proportions were then analyzed by flow cytometry. For lung tissue analysis, the left lung was excised, minced into fine pieces, and transferred to a centrifuge tube. A digestion solution containing DNase, hyaluronidase, and collagenase IV was added, and the mixture was incubated at 37 °C for 30 min with gentle agitation. The digested tissue was filtered through a 70 μm cell strainer, centrifuged, and red blood cells were lysed using a red blood cell lysis buffer. After the final centrifugation, the cell pellet was incubated with neutrophil-specific antibodies for 30 min in the dark. Cells were subsequently washed with PBS, centrifuged at 1200 rpm for 5 min, and resuspended in 200 μL of PBS. The proportion of neutrophils was quantified by flow cytometry [41]. Pathological sections Twenty-four hours after LPS-induced ARDS modeling, the left lung was harvested and fixed in 4% paraformaldehyde for 24 h. The tissue was then subjected to sequential gradient dehydration, paraffin embedding, and sectioning, followed by hematoxylin and eosin (H&E) staining. For immunofluorescence histochemistry, following antigen retrieval and blocking, the sections were incubated with primary antibodies against NOD-like receptor protein 3 (NLRP3) inflammasome, caspase-1, and phosphorylated dynamin-related protein 1 (p-Drp1) overnight at 4 °C. After thorough washing, the sections were incubated with fluorescently labeled secondary antibodies for 1 h at room temperature. Subsequently, the sections were counterstained with DAPI for 3 min and examined under a fluorescence microscope. The degree of lung tissue injury in H&E-stained sections was evaluated using a standardized scoring system in a double-blind manner. For immunofluorescence-labeled sections, images were captured using a fluorescence microscope, and fluorescence intensity was quantified using Image J software. Wet/dry (W/D) ratio measurement The right lower lung lobe was excised, thoroughly rinsed with PBS, and gently blotted with filter paper to remove residual surface moisture. The wet weight was immediately recorded. Subsequently, the tissue was dried in an oven at 60 °C for 72 h, after which the dry weight was measured. The wet-to-dry (W/D) ratio was calculated by dividing the wet weight by the dry weight and served as an indicator of pulmonary edema. A more pronounced inflammatory response is associated with increased pulmonary edema, resulting in a higher W/D ratio. Western blot analysis The right lower lung lobe was collected, weighed, and homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with phosphatase and protease inhibitor cocktails and EDTA at optimized ratios. The lysates were centrifuged at 12,000 rpm for 15 min, and the resulting supernatant was used for bicinchoninic acid (BCA) protein quantification to ensure equal protein loading across samples. Protein samples (40 μg per lane) were separated on a 10% polyacrylamide gel by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Following electrophoresis, proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with a rapid blocking buffer to minimize non-specific binding. After washing, it was incubated with primary antibodies overnight at 4 °C, followed by incubation with secondary antibodies for 1 h at room temperature. Finally, the PVDF membrane was immersed in a chemiluminescent substrate and visualized using an enhanced chemiluminescence (ECL) detection system (Thermo Fisher Scientific, Waltham, MA, USA) to detect protein signals [39]. Animal targeting and safety detection To evaluate the lung-targeting capability of DTP-LSA@MTC NPs in ARDS model, DiR-labeled DTP-LSA@MTC NPs and DP@MTC NPs were intravenously administered to mice with ARDS and healthy controls, respectively. Fluorescence intensity in lung tissue was quantified using an in vivo fluorescence imaging system at 0, 1, 2, 4, 6, 8, and 24 h post-injection. For nanoparticle safety assessment, thirty C57BL/6 mice were randomly assigned to six groups (n = 5 per group). Each mouse received an intravenous injection of 100 μL of DTP-LSA@MTC NPs containing 6 mg/mL MDI. At 0, 1, 3, 7, 14, and 28 days after administration, blood samples and major organs (heart, liver, spleen, lung, and kidney) were collected under anesthesia induced by sodium pentobarbital. Blood specimens were analyzed for biochemical parameters and complete blood count, while the harvested organs were fixed in 4% paraformaldehyde and processed for hematoxylin and eosin (H&E) staining [42]. To assess the pharmacokinetic characteristics of Ce and clarify the in vivo absorption, distribution and elimination behaviors of DTP-LSA@MTC NPs. Briefly, another cohort of C57BL/6 mice (n = 3 at each time point) were intravenously injected with 100 μL of DTP-LSA@MTC NPs in accordance with the identical administration regimen. At 1, 6, 12, 24 and 48 h post-injection, mice were anesthetized with sodium pentobarbital, and approximately 0.3–0.5 mL of orbital venous blood was collected into centrifuge tubes. The blood samples were centrifuged at 3000 rpm for 15 min at 4 °C to isolate serum, which was stored at −80 °C until further detection. The serum Ce concentration was quantified via inductively coupled plasma mass spectrometry (ICP-MS) following standard operating procedures. For investigating the tissue distribution and in vivo metabolism of Ce in major organs, additional mice were randomly divided into two groups (n = 3 per group) and subjected to the same intravenous injection of DTP-LSA@MTC NPs. All mice were euthanized under sodium pentobarbital anesthesia at 1 day and 14 days after drug administration, respectively. Major organs including heart, liver, spleen, lung and kidney were rapidly excised, thoroughly rinsed with pre-cooled normal saline to eliminate residual blood, blotted dry with filter paper and precisely weighed. Subsequently, the organ tissues were homogenized, and the Ce content in tissue homogenates was determined by ICP-MS. By comparing Ce levels at the two predetermined time points, the distribution pattern and metabolic tendency of Ce in various organs were analyzed, which further clarified the in vivo metabolic fate and clearance profile of DTP-LSA@MTC NPs. Statistics All statistical data are presented as mean ± standard deviation. The normality of the datasets was evaluated using the Shapiro–Wilk test and the Kolmogorov–Smirnov test, with a significance level set at 0.05. To assess the assumption of homogeneity of variance, the Brown–Forsythe test and Bartlett's test were conducted, with a significance threshold of P > 0.05. Statistical differences between groups were analyzed using one-way analysis of variance (ANOVA) or Student's t-test. A P value of less than 0.05 was considered statistically significant. GraphPad Prism version 9.51 and SPSS version 20.0 were used for data analysis. Ethics approval All animal experiments were conducted under the Guidance of Animal Management Rules of the Ministry of Health of the People's Republic of China (Document No. 55, 2001) with approval from the Animal Ethics Committee of The Second Affiliated Hospital of Chongqing Medical University Chongqing (IACUC-SAHCQMU-2024-00089). Consent for publication All authors have agreed to publish this article. Funding This work was financially supported by the Chongqing Talents: Chongqing Science and Health Joint Key Project (2025ZDXM037), the Second Affiliated Hospital of 10.13039/501100004374Chongqing Medical University Peak Discipline Cluster Joint Project (2024318), 10.13039/501100001809National Natural Science Foundation of China (Grant No. 82302218, 82171946), and 10.13039/501100005230Natural Science Foundation of Chongqing (Grant No. CSTB2024NSCQ-MSX1151, CSTB2024NSCQ-MSX0172). National Key Laboratory of Neuropharmacology and oncology (SKLSIM-20251007). CRediT authorship contribution statement Ming He: Conceptualization, Data curation, Investigation, Methodology, Resources, Validation, Writing – original draft. Peng Zhang: Data curation, Investigation, Methodology, Visualization. Suya Bao: Investigation, Resources. Rui Luo: Formal analysis, Supervision. Li Chen: Investigation, Resources, Writing – original draft. Wenqi Huang: Data curation, Methodology, Writing – review & editing. Weixi Jiang: Project administration, Supervision, Writing – review & editing. An Zhang: Funding acquisition, Project administration, Supervision, Writing – review & editing. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: An Zhang has patent #202510026207.4 pending to Ming He, Peng Zhang, An Zhang. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.